-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Veru Names Joel Batten Exec VP, Head Of Its US Infectious Disease Franchise
Veru Names Joel Batten Exec VP, Head Of Its US Infectious Disease Franchise
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022.
Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North America where he was responsible for the Synagis business with gross revenue of approximately $600M and a team of over 160 employees. Mr. Batten led sales and marketing for the RSV Franchise as well as strategy for market access, distribution and patient access services. Prior to Sobi, he spent approximately 20 years in a number of positions of increasing responsibility at AstraZeneca / MedImmune and Sanofi Aventis in various infectious disease franchises including commercial infrastructure build-out, product launch, sales management, marketing, public health sales, and government affairs.
"Joel is an accomplished commercial leader with extensive knowledge in viral infectious disease product commercialization," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We are excited to have Joel join Veru at such a critical juncture in our Company's history as we build on the momentum of our positive Phase 3 sabizabulin for COVID-19 trial, our planned EUA submission, and the transition to delivering sabizabulin, if EUA is granted, to hospitalized COVID-19 patients at high risk for ARDS. Joel will be the head of our newly formed U.S. Infectious Disease Franchise and will be responsible for developing and leading all aspects of our U.S. go-to-market strategy for sabizabulin for COVID, if authorized, as well as planned future indications for other viral and ARDS-related and inflammatory diseases."
Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022.
VERU公司(納斯達克代碼:VERU)是一家專注於開發治療新冠肺炎和其他病毒性疾病和ARDS相關疾病以及治療乳腺癌和前列腺癌的新藥的生物製藥公司。該公司今天宣佈,任命喬爾·巴滕為執行副總裁兼其美國傳染病專營權的負責人,自2022年5月23日起生效。
Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus (RSV) Franchise at Sobi North America where he was responsible for the Synagis business with gross revenue of approximately $600M and a team of over 160 employees. Mr. Batten led sales and marketing for the RSV Franchise as well as strategy for market access, distribution and patient access services. Prior to Sobi, he spent approximately 20 years in a number of positions of increasing responsibility at AstraZeneca / MedImmune and Sanofi Aventis in various infectious disease franchises including commercial infrastructure build-out, product launch, sales management, marketing, public health sales, and government affairs.
最近,巴頓先生一直擔任SOBI北美公司呼吸道合胞病毒(RSV)專營權的負責人,負責Synagis業務,毛收入約為6億美元,擁有超過160名員工。巴頓先生負責RSV專營權的銷售和營銷,以及市場準入、分銷和患者准入服務的戰略。在加入SOBI之前,他在阿斯利康/醫療免疫公司和賽諾菲安萬特擔任了大約20年的多個職位,負責各種傳染病特許經營,包括商業基礎設施建設、產品推出、銷售管理、市場營銷、公共衞生銷售和政府事務。
"Joel is an accomplished commercial leader with extensive knowledge in viral infectious disease product commercialization," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We are excited to have Joel join Veru at such a critical juncture in our Company's history as we build on the momentum of our positive Phase 3 sabizabulin for COVID-19 trial, our planned EUA submission, and the transition to delivering sabizabulin, if EUA is granted, to hospitalized COVID-19 patients at high risk for ARDS. Joel will be the head of our newly formed U.S. Infectious Disease Franchise and will be responsible for developing and leading all aspects of our U.S. go-to-market strategy for sabizabulin for COVID, if authorized, as well as planned future indications for other viral and ARDS-related and inflammatory diseases."
Veru公司董事長、總裁兼首席執行官、醫學博士米切爾·施泰納説:“喬爾是一位有成就的商業領袖,在病毒傳染病產品商業化方面有豐富的知識。喬爾將成為我們新成立的美國傳染病專營店的負責人,如果獲得授權,我們將負責開發和領導我們治療慢性阻塞性肺疾病的美國薩比布林的美國上市戰略。我們很高興喬爾能在我們公司歷史的這樣一個關鍵時刻加入VERU,我們鞏固了我們新冠肺炎試驗的第三階段薩比布林的積極勢頭,我們計劃中的歐洲藥物治療方案,以及如果獲得批准,向住院的患有急性呼吸窘迫綜合徵的住院患者提供薩比布林的過渡。喬爾將成為我們新成立的美國傳染病特許經營權的負責人,並將負責開發和領導我們治療慢性阻塞性肺疾病的薩比布林的美國上市戰略的所有方面,以及計劃中的未來其他病毒和與急性呼吸窘迫綜合徵相關的炎症性疾病的適應症。“
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧